See more : TrueCar, Inc. (TRUE) Income Statement Analysis – Financial Results
Complete financial analysis of Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Infant Bacterial Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Radix Industries (India) Limited (RADIXIND.BO) Income Statement Analysis – Financial Results
- Pokfulam Development Company Limited (0225.HK) Income Statement Analysis – Financial Results
- Sarthak Metals Limited (SMLT.NS) Income Statement Analysis – Financial Results
- H-Farm S.p.A. (FARM.MI) Income Statement Analysis – Financial Results
- Gravity (India) Limited (GRAVITY.BO) Income Statement Analysis – Financial Results
Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.00K | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 238.00K | 162.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 816.00K | 816.00K | 0.00 | 811.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 77.00K | 12.00K | 0.00 | 0.00 | -816.00K | -816.00K | 238.00K | -649.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | -400.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 121.18M | 65.82M | 44.67M | 72.23M | 47.20M | 39.42M | 36.38M | 40.80M | 17.97M | 6.59M | 228.83K | 0.00 |
| General & Administrative | 13.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54M | 2.60M | 0.00 | 0.00 | 0.00 |
| SG&A | 14.58M | 1.02M | 1.12M | 1.14M | 1.24M | 1.09M | 957.00K | -2.54M | 2.60M | 0.00 | 0.00 | 0.00 |
| Other Expenses | -1.07M | -12.00K | -94.00K | -312.00K | 0.00 | 0.00 | 0.00 | -2.54M | 41.00K | 0.00 | 0.00 | -1.71K |
| Operating Expenses | 134.69M | 65.81M | 44.58M | 71.92M | 47.20M | 39.42M | 36.38M | 38.25M | 20.62M | 6.59M | 431.00 | -1.71K |
| Cost & Expenses | 134.69M | 65.81M | 44.58M | 71.92M | 47.20M | 39.42M | 36.38M | 38.25M | 20.62M | 6.59M | 431.00 | -1.71K |
| Interest Income | 11.55M | 650.00K | 413.00K | 214.00K | 1.61M | 327.00K | 0.00 | 0.00 | 0.00 | 1.00K | 431.00 | 1.71K |
| Interest Expense | 0.00 | 293.00K | 413.00K | 303.00K | 725.00K | 1.52M | 15.00K | 16.00K | 9.00K | 156.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 134.62M | 816.00K | 816.00K | 816.00K | 816.00K | 816.00K | 816.00K | 811.00K | 20.62M | 1.00K | 228.83K | 0.00 |
| EBITDA | 11.55M | -65.45M | -44.99M | -72.01M | -45.50M | -39.79M | -35.33M | -37.30M | 0.00 | -17.04K | 0.00 | -1.71K |
| EBITDA Ratio | 14,998.70% | -536,183.33% | 0.00% | 0.00% | 0.00% | 0.00% | -14,842.44% | -23,011.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -134.62M | -65.81M | -44.58M | -71.92M | -47.20M | -39.42M | -36.14M | -38.09M | -20.62M | -6.59M | -228.83K | -1.71K |
| Operating Income Ratio | -174,827.27% | -548,400.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,185.29% | -23,512.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.55M | 357.00K | -413.00K | -89.00K | 880.00K | -1.19M | -15.00K | -16.00K | -9.00K | -155.18K | 228.83K | -1.71K |
| Income Before Tax | -123.07M | -65.45M | -44.99M | -72.01M | -46.32M | -40.61M | -36.16M | -38.11M | -20.62M | -6.75M | 0.00 | -1.71K |
| Income Before Tax Ratio | -159,828.57% | -545,425.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,191.60% | -23,522.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -357.00K | 413.00K | 303.00K | 725.00K | 327.00K | 0.00 | 0.00 | -20.62M | 0.00 | 0.00 | 0.00 |
| Net Income | -123.07M | -65.09M | -45.40M | -72.31M | -47.05M | -40.61M | -36.16M | -38.11M | -20.62M | -6.75M | 0.00 | -1.71K |
| Net Income Ratio | -159,828.57% | -542,450.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,191.60% | -23,522.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.95 | -5.80 | -4.04 | -6.44 | -4.19 | -3.76 | -6.46 | -7.54 | -10.06 | -2.02 | 0.00 | 0.00 |
| EPS Diluted | -9.95 | -5.80 | -4.04 | -6.44 | -4.19 | -3.76 | -6.46 | -7.54 | -10.06 | -2.02 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 12.36M | 11.23M | 11.23M | 11.23M | 11.23M | 10.79M | 5.60M | 5.06M | 2.05M | 3.34M | 2.04M | 2.04M |
| Weighted Avg Shares Out (Dil) | 12.36M | 11.23M | 11.23M | 11.23M | 11.23M | 10.79M | 5.60M | 5.06M | 2.05M | 3.34M | 2.04M | 2.04M |
Source: https://incomestatements.info
Category: Stock Reports